The PE Ratio as of November 2024 (TTM) for InflaRx N.V. (IFRX) is -1.79

According to InflaRx N.V.’s latest financial reports and current stock price. The company's current PE Ratio is -1.79. This represents a change of -33.67% compared to the average of -2.70 of the last 4 quarters.

InflaRx N.V. (IFRX) Historical PE Ratio (quarterly & annually)

How has IFRX PE Ratio performed in the past?

The mean historical PE Ratio of InflaRx N.V. over the last ten years is -16.88. The current -1.79 PE Ratio has changed 960.52% with respect to the historical average. Over the past ten years (40 quarters), IFRX's PE Ratio was at its highest in in the June 2022 quarter at 7.54. The PE Ratio was at its lowest in in the June 2016 quarter at -74.08.

InflaRx N.V. (IFRX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of InflaRx N.V. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

InflaRx N.V. (IFRX) Average PE Ratio

How has IFRX PE Ratio performed in the past?

The current PE Ratio of InflaRx N.V. (IFRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

InflaRx N.V. (IFRX) PE Ratio vs. Peers

How is IFRX’s PE Ratio compared to its peers?

InflaRx N.V.’s PE Ratio is less than Generation Bio Co. (-0.91), less than Kronos Bio, Inc. (-0.56), greater than Erasca, Inc. (-3.95), greater than C4 Therapeutics, Inc. (-4.26), greater than Edgewise Therapeutics, Inc. (-27.83), greater than Kezar Life Sciences, Inc. (-5.24), greater than Fulcrum Therapeutics, Inc. (-10.02), less than Passage Bio, Inc. (-0.49), greater than Acumen Pharmaceuticals, Inc. (-2.73), less than Galera Therapeutics, Inc. (-0.09), greater than Inozyme Pharma, Inc. (-3.09), greater than Eledon Pharmaceuticals, Inc. (-2.72), greater than Icosavax, Inc. (-8.27), greater than Ocuphire Pharma, Inc. (-2.14), less than Reviva Pharmaceuticals Holdings, Inc. (-1.05), greater than Protalix BioTherapeutics, Inc. (-6.39), greater than EyePoint Pharmaceuticals, Inc. (-7.17), greater than SELLAS Life Sciences Group, Inc. (-1.96), greater than Monte Rosa Therapeutics, Inc. (-4.83), greater than Design Therapeutics, Inc. (-5.95), greater than Werewolf Therapeutics, Inc. (-1.83), less than Ikena Oncology, Inc. (-1.24), greater than Stoke Therapeutics, Inc. (-7.05),

Build a custom stock screener for InflaRx N.V. (IFRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like InflaRx N.V. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

InflaRx N.V. (IFRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like InflaRx N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.